Chimeric toxins

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 3816

Patent

active

057030391

ABSTRACT:
A chimeric toxin comprising protein fragments joined together by peptide bonds, the chimeric toxin comprising, in sequential order, beginning at the amino terminal end of the chimeric toxin,
(a) the enzymatically active Fragment A of diphtheria toxin,
(b) a first fragment including the cleavage domain 1.sub.1 adjacent the Fragment A of diphtheria toxin,
(c) a second fragment comprising at least a portion of the hydrophobic transmembrane region of Fragment B of diphtheria toxin, the second fragment having a deletion of at least 50 diphtheria toxin amino acid residues, the deletion being C-terminal to the portion of the transmembrane region, and the second fragment not including domain 1.sub.2, and
(d) a third fragment comprising a portion of a cell-specific polypeptide ligand, the portion including at least a portion of the binding domain of the polypeptide ligand, the portion of the binding domain being effective to cause the chimeric toxin to bind selectively to a predetermined class of cells to be attacked by the enzymatically active Fragment A, the chimeric toxin possessing any of, greater toxicity than that of a toxin comprised of DAB.sub.486 fused to the third fragment, a lower K.sub.d for the sites on cells of the predetermined class to which the chimeric toxin binds than that of a toxin comprised of DAB.sub.486 fused to the third fragment, greater resistance to proteolytic degradation than that exhibited by a toxin comprised of DAB.sub.486 fused to the third fragment, greater resistance to the inhibition of its cytotoxicity by the cell-specific polypeptide ligand than that exhibited by DAB.sub.486 fused to the third fragment, the ability to inhibit protein synthesis to a given degree by a period of exposure that is shorter than the period of exposure required by DAB.sub.489 fused to the third fragment to inhibit protein synthesis to the same degree, or the ability to effect a more rapid onset of the inhibition of protein synthesis than that exhibited by DAB.sub.486 fused to the third fragment.

REFERENCES:
patent: 4468382 (1984-08-01), Bacha
patent: 4675382 (1987-06-01), Murphy
patent: 4830962 (1989-05-01), Gelfand et al.
Edward, et al., Mol. Cell Biol. 9(7):2860-67 (1989).
Lambotte, et al., J. Cell Biol. 87:837-40 (1980).
Colombatti, et al., J. Biol. Chem. 261(7):3030-35 (1986).
Greenfield, et al., PNAS USA 80:6853-57 (1983).
Boguet, et al., PNAS USA 73:4449-53 (1976).
Bacha, et al., J. Biol. Chem. 258(3):1565-70 (1983).
Cabiaux, et al., J. Biol. Chem. 264(9):4928-38 (1989).
Rappuoli, et al., J. Bacteriol. 153:1202-10 (1983).
Bacha, et al., J. Exp. Med. 167:612-22 (1988).
Williams, et al., in Protein Engineering 1:493-98 (1987).
Bishai, et al., J. Bacteriol. 169(4):1554-63 (1987).
D. Williams, et al., "Structure/Function Analysis of IL-2 Toxin," in Protein Society Meeting, Aug. 1989, Abstract T 71.
Greenfield, et al., Science 238:536-39 (1987).
Simpson, et al., Cell 29:469-473 (1982).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Chimeric toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric toxins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-202226

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.